TSLPR

-- Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued clinical advancement of ADX-097 -- WALTHAM, Mass., Oct. 14, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that it will present clinical data supporting its program for innate immunity, ADX-097, at the American Society of Nephrology (ASN) Kidney Week 2024, taking place October 24-27, 2024, in San Diego, Calif. Abstracts are available here. ADX-097, Q32 Bio's lead product candidate from its tissue-targeted complement inhibitor platform, is a humanized anti-C3d mAb fusion protein being evaluated for the treatment of patients with renal diseases associated with increased complement activation. "We look forward to presenting our promising clinical data at ASN Kidney Week 2024 that supports the continued advancement of ADX-097, our novel tissue-targeted inhibitor of complement activation designed to inhibit complement in the diseased tissue and minimize systemic complement blockade," said Shelia Violette, Ph.D., Chief Scientific Officer of Q32 Bio. "In our Phase 1 clinical trial, ADX-097 was observed to be generally well-tolerated with desirable pharmacokinetics and pharmacodynamics (PK/PD) properties. We believe ADX-097 has the potential to achieve relevant complement inhibition directly in the tissue while sparing systemic activity, with the goal of addressing limitations of the currently available systemic approaches, including infection risk and the need for high drug doses and frequent administration to achieve therapeutic levels of complement inhibition." "These first-in-human data for ADX-097 that we will share at Kidney Week demonstrate the potential of our novel and differentiated approach to inhibiting the complement system, a validated biologic target," said Jodie Morrison, Chief Executive Officer of Q32 Bio. "We remain focused on advancing our pipeline of programs targeting the immune system for the treatment of autoimmune and inflammatory diseases, including ADX-097 in two Phase 2 clinical trials." Presentation Details: Abstract Title: ADX-097, a Tissue-Targeted Complement Inhibitor for the Treatment of Renal Diseases: Phase 1 Results in Healthy Participants and Model-Informed Phase 2 Dose Selection Presenter: Dr. Bernd Jilma, M.D., Professor, Department of Clinical Pharmacology, Medical University of Vienna, Austria Date & Time: Saturday, October 26, 2024, from 10:00 a.m. to 12:00 p.m. PT Session Type: Poster Session Title: C3G, TMA, MGRS, Amyloidosis, and More Abstract ID: 4123429 Summary: ADX-097, a C3d mAb – fH fusion protein, was designed to inhibit complement in the diseased kidney while avoiding systemic blockade, providing the potential for an enhanced activity and safety profile. In a Phase 1 ascending dose clinical study of ADX-097 in healthy volunteers, ADX-097 demonstrated a favorable safety profile and desired PK/PD properties, supporting a Phase 2 dose that is predicted to provide tissue inhibition of complement in glomerular diseases while sparing systemic complement activity. About ADX-097 ADX-097, the lead product candidate from Q32 Bio's tissue-targeted complement inhibitor platform, is a humanized anti-C3d mAb fusion protein. ADX-097 is designed to restore complement regulation—an integral part of the innate immune system—through a novel, tissue-targeted mechanism. Q32 Bio is currently evaluating ADX-097 in an open-label Phase 2 renal basket clinical trial and is planning to evaluate ADX-097 in a Phase 2 clinical trial in ANCA-Associated Vasculitis (AAV). About Q32 Bio Q32 Bio is a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio's lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Q32 Bio's program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase 2 trials for the treatment of atopic dermatitis and alopecia areata. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases. Q32 Bio's program for innate immunity, ADX-097, is based on a novel platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade – a key differentiator versus current complement therapeutics. Q32 Bio has completed a first-in-human, Phase 1 ascending dose clinical study of ADX-097 in healthy volunteers. For more information, visit . Availability of Other Information About Q32 Bio Investors and others should note that we communicate with our investors and the public using our company website , including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that we post on our website or on X or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Forward-Looking Statements This communication contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, relating to our business, operations and financial condition, including but not limited to current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and related timing, including statements regarding expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of Q32 Bio's product candidates, including ADX-097, and anticipated milestones and timing, among others. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "anticipate," "plan," "likely," "believe," "estimate," "project," "intend," and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; data generated from our preclinical and clinical studies such as our Phase 2 clinical trials of ADX-097, may not meet our expectations; our product candidates may not provide the intended therapeutic benefits; our product candidates may cause serious adverse side effects; the ability to integrate our business with our merger partner successfully and to achieve anticipated synergies; the possibility that other anticipated benefits of the merger will not be realized, including without limitation, anticipated revenues, expenses, earnings and other financial results, and growth and expansion of our operations, and the anticipated tax treatment of the merger; our ability to retain, attract and hire key personnel; potential adverse reactions or changes to relationships with employees, suppliers or other parties resulting from the completion of the merger; potential business uncertainty, including changes to existing business relationships that could affect our financial performance; the need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; the inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties, including for the manufacture of materials for our research programs, preclinical and clinical studies; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; securities class action litigation; the impact of global pandemics and general economic conditions on our business and operations, including the our preclinical studies and clinical trials; the possibility of system failures or security breaches; risks relating to intellectual property; significant costs incurred as a result of operating as a public company; and such other factors as are set forth in Q32 Bio's periodic public filings with the SEC, including but not limited to those described under the heading "Risk Factors" in our Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024 and any subsequent filings made with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. Contacts: Investors: Brendan Burns Media: Sarah Sutton Argot Partners 212.600.1902 [email protected] SOURCE Q32 Bio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Boston-area biotechs Upstream Bio and CAMP4 Therapeutics are headed to the Nasdaq on Friday, the latest companies to IPO in what appears to be a recovery for startups trying to raise capital on the public market. Upstream Bio priced at $17 per share, the high end of the $15 to $17 range it set earlier this week . By selling 15 million shares — 2.5 million more than originally planned — it will raise $255 million in new cash. CAMP4, meanwhile, priced its shares $CAMP at $11 apiece, $3 below the low end of the $14 to $16 range it marketed to investors. It sold 6.82 million shares versus an initial plan to offer 5 million and will raise $75 million . The IPO window is “showing signs of recovery,” Oppenheimer bankers wrote in a quarterly analysis this week. GPCR biotech Septerna is also in the IPO queue, and Bain-backed obesity startup Rivus Pharmaceuticals is also considering a listing this fall, Bloomberg reported this week. For Upstream $UPB the offering will add to its coffers as it runs Phase 2 and later-stage trials of its TSLP receptor antagonist verekitug. The experimental treatment, licensed from Astellas, is being studied for severe asthma and chronic rhinosinusitis with nasal polyps . Upstream hopes to enter a similar market as Amgen and AstraZeneca’s Tezspire, as well as Blackstone-backed Uniquity Bio’s solrikitug . CAMP4 is working on regulatory RNA and has a Phase 1 trial of its lead drug, a CPS1-targeting medicine for urea cycle disorders. The IPO comes a few weeks after CAMP4 added BioMarin to its partnership lineup, which already includes Fulcrum Therapeutics and Eli Lilly. Earlier in its startup days, CAMP4 had pacts with Biogen and Alnylam.

Asthma patients have many drug options, but many patients find these choices either inconvenient or inadequate for severe cases of the chronic respiratory condition. Upstream Bio is pursuing a validated immunological target with a drug it contends offers dosing and efficacy advantages over a commercialized asthma medication from AstraZeneca and Amgen, and the biotech now has $225 million in IPO cash to help build its case with clinical data. Investors are persuaded by Upstream’s ambition, and their interest in the biotech’s new stock enabled the company to boost the deal size. After setting preliminary IPO terms of 12.5 million shares in the range of $15 to $17 each, which would have raised $200 million at the pricing midpoint, the Waltham, Massachusetts-based biotech on Thursday ended up offering 15 million shares at the top of the targeted price range. Upstream’s shares now trade on the Nasdaq under the stock symbol “UPB.” On Friday, Upstream’s first day on the public markets, the company’s stock price closed at $22, up 29.4% from the IPO price. Severe asthma is defined as disease that is uncontrolled despite treatment with high-dose inhaled corticosteroids. It can also be asthma that requires high-dosed inhaled corticosteroids to prevent symptoms from becoming uncontrolled. Biologic drugs offer patients an alternative treatment option for cases of uncontrolled asthma. Upstream’s lead drug is verekitug, a monoclonal antibody designed to block thymic stromal lymphopoietin, or TSLP. This signaling protein plays a role in immunological disorders and it’s upstream of multiple signaling cascades involved in many immune-mediated diseases, the company said in its IPO filing. presented by Sponsored Post The Promise of Value-Based Care and MedTech Innovation Monica Vajani, Executive Director for mHUB’s MedTech Accelerator, discusses how mHUB is helping innovators transition healthcare towards value-based care. By Monica Vajani - mHUB Of the six biologic drugs currently approved for severe asthma, only the AstraZeneca and Amgen product Tezspire addresses TSLP. But while Tezspire blocks the TSLP ligand, Upstream’s drug blocks the TSLP receptor. Upstream contends its approach could offer better control of asthma symptoms. It also offers potential for less frequent dosing. The company is testing dosing every 12 weeks and every 24 weeks — a much lower dosing burden compared to once monthly injections of Tezspire. “We believe that by reducing the frequency of dosing we can increase patient compliance with biologic treatments for severe asthma,” Upstream said in its IPO filing. “Additionally, a less frequent dose interval may appeal to patients that are not satisfied with their current treatment plan or are unwilling to take current biologics due to the treatment burden that comes with frequent dosing.” In Phase 1b testing, Upstream reported its drug led to “rapid and complete TSLP receptor occupancy.” Results also showed reductions in biological indicators of asthma that were sustained for up to 24 weeks after the last dose. Tezspire, which won FDA approval in 2021, was not part of this study as a comparator. But Upstream said verekitug’s results show it was about 300-fold more potent than the AstraZeneca and Amgen product based on published data for that drug. The Phase 1b results were presented in May during the American Thoracic Society International Conference. A Phase 2 test of verekitug in severe asthma began this past March; preliminary data are expected in the second half of 2026. Upstream’s approach to blocking TSLP has potential in other immunological conditions. A Phase 2 test in chronic rhinosinusitis with nasal polyps is expected to yield data in the second half of 2025. A separate mid-stage trial in chronic obstructive pulmonary disease (COPD) is expected to begin in the second half of next year. sponsored content Upcoming Webinar: Battle of the Budget: Employers vs. Rising Healthcare Costs Gain valuable knowledge and practical insights on how employers are addressing an increasingly complex healthcare budget landscape. By Personify Health Verekitug was discovered by Astellas Pharma, which advanced the drug candidate to Phase 1 testing. In 2021, months after Upstream formed, the young company acquired the Astellas asset for $81.1 million, according to the filing. There are no future payments owed to the Japanese pharma company. Upstream had raised $400 million from investors prior to the IPO, according to the filing. The company’s most recent financing was a $150 million Series B round announced in June and led by Enavate Sciences and Venrock Healthcare Capital Partners. Orbimed is Upstream’s largest shareholder with a 9.9% post-IPO stake, the filing shows. As of the end of June, the company reported its cash position was $235.8 million. Now that Upstream is public, the company plans to spend $150 million to continue the ongoing Phase 2 test of its lead program in severe asthma and advance it into Phase 3. About $40 million is budgeted for completing a Phase 2 test of the molecule in chronic rhinosinusitis with nasal polyps and starting a Phase 3 test in this indication. Another $50 million is set aside for costs associated with verekitug drug substance, including manufacturing. The company said it expects its capital will be sufficient to fund operations through mid-2027. CAMP4 Therapeutics Corrals $75M for Trials With a New Kind of RNA Therapy CAMP4 Therapeutics, a company named for the final camp before the summit of Mount Everest, has $75 million in IPO cash to continue development of treatments for haploinsufficiencies, disorders in which dysfunction in one copy of a gene leads to abnormally low levels of a key protein. The Cambridge, Massachusetts-based biotech aims to treat disease by targeting regulatory RNA, or regRNA, a type of RNA that regulates gene expression. The CAMP4 drugs are antisense oligonucleotides that bind to regRNA and get it to dial up gene expression. In a 2021 interview, CAMP4 CEO Josh Mandel-Brehm compared the approach to using a rheostat to adjust an electrical current. The company’s drugs, called RNA actuators, amplify gene expression in a controllable way, he said. Metabolic and central nervous system haploinsufficiencies are the company’s initial areas of focus. Lead program CMP-CPS-001 is in development for urea cycle disorders, inherited metabolic diseases that render the body unable to properly convert ammonia into urea. CAMP4’s drug is designed to amplify expression of an enzyme that catalyzes the first step of the urea cycle. In preclinical research, results showed a lowering of ammonia levels to normal ranges. A Phase 1 test is underway in healthy volunteers. Data from the single dose ascending portion of the trial are expected in the first quarter of 2025; the multiple ascending dose portion is expected to have data in the second half of next year. The next program in the pipeline is a preclinical treatment for SYNGAP1-related disorders, neurodevelopmental conditions caused by pathogenic variants in the SYNGAP1 gene. This haploinsufficiency leads to SYNGAP levels up to 50% below the normal range. CAMP4 had raised $183.3 million prior to its IPO. The company’s most recent financing was a $100 million Series B round in 2022 led by Enavate Sciences. Enavate is CAMP4’s largest shareholder with a 13.7% post-IPO stake, followed by 5AM Ventures with an 11.4% stake, the filing shows. As of the end of the second quarter of this year, CAMP4 reported a $12.6 million cash position. With the IPO proceeds, the company plans to spend $26 million to complete the Phase 1 test of its lead drug candidate for urea cycle disorders. About $18 million is set aside for continuing preclinical development of the SYNGAP1 program. Another $10 million is budgeted for expanding CAMP4’s platform technology and for development of other programs in the preclinical and discovery stages. CAMP4 was able to raise the money it needs for its plans, but it had to significantly cut its IPO price to do so. In preliminary IPO terms set earlier this week, CAMP4 planned to offer 5 million shares in the range of $14 and $16 each, which would have raised $75 million at the pricing midpoint. CAMP4 reached its $75 million goal by offering 6.82 million shares priced at $11 apiece. Those shares are trading on the Nasdaq under the stock symbol “CAMP.” CeriBell Upsizes IPO to Support a Commercialized EEG Tech Employing AI Medical technology company CeriBell raised $180.3 million to bolster commercialization efforts for its FDA-cleared electroencephalography (EEG) technology. The Ceribell System uses artificial intelligence to aid in the detection and management of seizures. The hardware is a disposable headband and a pocket-sized recorder that captures and wirelessly transmits EEG signals. An AI-powered seizure detection algorithm continuously monitors the patient’s EEG signal to detect seizures. Ceribell System, which is used in intensive care units and emergency departments, commercially launched in 2018. Sunnyvale, California-based CeriBell has two sources of recurring revenue: sales of the disposable headbands and a monthly subscription fee charged to the hospital customers that use the company’s technology. In 2023, CeriBell reported $45.2 million in total revenue, a 74% increase compared to the prior year. In the first half of this year, revenue was $29.7 million, a 45% increase compared to the same period in 2023. As of the end of September, CeriBell reported its cash position was $14 million. With the IPO proceeds, CeriBell plans to use $90 million for sales and marketing and $20 million for research and product development. CeriBell was able to upsize its IPO. In preliminary financial terms set earlier this week, the company estimated it would raise $88.9 million. The company revised those terms early Thursday, aiming to offer 6.7 million shares in the range of $16 to $17 each, which would have raised $174.9 million at the pricing midpoint. When the company finally priced its IPO late Thursday, it ended up offering 10.6 million shares priced at the top of the range. CeriBell’s shares trade on the Nasdaq under the stock symbol “CBLL.” Image: Jackie Niam, Getty Images